好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

CIDP Disease Burden: Results of a US Nationwide Patient Survey
Autoimmune Neurology
P2 - Poster Session 2 (5:30 PM-6:30 PM)
15-104

To assess the impact of chronic inflammatory demyelinating polyneuropathy (CIDP) disease-related disability and treatment on domestic arrangements, and work activities.

Although CIDP is treatable, disease-related disability is common. The extent to which disability impacts domestic arrangements, or work activities is not well characterized.

Data from an online survey of 475 individuals, aged ≥18 years, recruited by the GBS/CIDP Foundation and self-reported to have CIDP, were used to assess disease and treatment burden. Data were analyzed overall and by stratification of patients based on the likelihood of an accurate CIDP diagnosis.

Patients were stratified into “likely CIDP” (n=187), “somewhat likely CIDP” (n=170), and “unlikely CIDP” (n=118) based upon questionnaire responses. Patients categorized as “likely CIDP” had symptoms when starting treatment which were loss of balance/coordination, weakness in hips/legs, and pain and numbness in hands and feet. Among all respondents, 24% moved to a new home and 40% made adaptive home changes after they were given a CIDP diagnosis. Moreover, 47% stopped working after the diagnosis, 20% missed school/work within the past month, and 14% made timing changes to their work environment. The most common treatments were intravenous immunoglobulin (IVIG) [63% currently using] and corticosteroids (19%). Corticosteroids were discontinued in 68% of users, among these 37% discontinued due to tolerability issues. A full day or more from school/work was missed with each infusion session in 27% of IVIG-treated patients and venous access difficulty was reported by 8%. A subgroup analyses (n=32) showed that benefits of SCIG administration and avoiding difficulties with IVIG infusion were the most common reasons for SCIG preference (81% and 38% respectively). Further analysis by stratification group will be presented.

Results from this nationwide survey demonstrate that both CIDP and commonly prescribed CIDP treatments are associated with disease and treatment burdens that impact school, work, and home activities.

Authors/Disclosures
Todd D. Levine, MD (Honor Health)
PRESENTER
Dr. Levine has received personal compensation for serving as an employee of CND life sciences . Dr. Levine has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Nufactor. Dr. Levine has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for PNA. Dr. Levine has or had stock in CND Life Sciences.Dr. Levine has or had stock in Corinthian reference lab.
Jeffrey A. Allen, MD (University of Minnesota) Dr. Allen has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Argenx. Dr. Allen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for csl behring. Dr. Allen has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Takeda. Dr. Allen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Grifols. Dr. Allen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alnylam. Dr. Allen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Allen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra Zeneca. Dr. Allen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Johnson and Johnson. Dr. Allen has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion. Dr. Allen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Annexon. Dr. Allen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Immunovant. Dr. Allen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Allen has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Dianthus. Dr. Allen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CSL Behring. Dr. Allen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Annexon. Dr. Allen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Dr. Allen has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Allen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Dianthus. Dr. Allen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for CSL behring. Dr. Allen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Takeda. Dr. Allen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alnylam. Dr. Allen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alexion. Dr. Allen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Johnson and Johnson.
No disclosure on file
Ann L. Bullinger, PharmD (CSL Behring) No disclosure on file
Carol L. Koski, MD No disclosure on file